Statistics from Altmetric.com
I read with great interest the article by Mease et al 1 because equivalence in efficacy with lesser secukinumab total doses could be less expensive to payers and more safe and comfortable to patients. However, I am somewhat disappointed with the reported results.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.